David Meeker: Yes. I would think as we’ve looked at I mean, right now, and this is again a dynamic scenario. I would put on the order of 20% of the states would have that relatively harder line. And those are the ones where some of those patients will move on to PAP as we continue to fight that battle. But the vast majority, 80% are either what we call the green category and patients are moving through with an unimpeded PAP or in a mixed category where there’s — the state is still working through its response, but we’ve had patients through. And then there’s a smaller segment that we still haven’t put a patient in front of that state. And so they were . But it is a relatively small percentage of the states today, which again I think is as a starting six months in, from my view, pretty amazing.
Michael Higgins: I appreciate that. One last one if I could. How many prescriptions are coming in outside of BBS. It can include on label as well as off. You’ve got some great data in HO obviously? I’m curious if there’s any prescriptions there that you’re aware of?
David Meeker: No. So none that we’re aware of. Again, we have the Phase 3 trial up and running. The actively screening has indicated, so there’s an opportunity for patients to engage there. But we don’t have any insight into patients who may be €œseeking off label for HO today€. For the other, again, I want to apologize. Just the POMC, LEPR world, again, we believe there’s tens of patients today and that’s a world, particularly in the U.S. we’ll see how Europe continues to open up slightly different dynamic as Yann described. But that in the 10s is what you should expect for POMC and LEPR.
Michael Higgins: I appreciate the feedback. Thanks, guys, and congrats again.
Operator: Please standby for our next question. Our next question comes from Joseph Stringer with Needham. Your line is now open.
Joseph Stringer: Hi, thanks for taking our question. Just going back to persistence rates for patients that have started on commercial drug and have discontinued, what are some of the main reasons that you’re hearing for that? Is there any particular reason that stands out?
David Meeker:
Jennifer Chien: Sure. At this point in time, there is a variety of different reasons that are more like one to two at this point of time. It could be hybrid pigmentation. It could be based off of sort of loss to follow-up opportunities. What I do find interesting is, there are several discontinued for personal reasons, but our opportunities for potential reinitiution of therapy moving forward. So our teams remain in contact with the patients even after discontinuation in case there is an interest in terms of reinitiating. And we’ve heard this also from several physicians as well that there may be opportunity in the future for re initiation.
David Meeker: And just to provide a little more context, it’s an important issue, which obviously we follow closely. So the current discount rate is in the mid-single digit percentage range. And as Jennifer highlighted, what’s really — I think, been highly reassuring is that the percentage of spaces that are stopping because of known side effect profiles, characterized on the order of third of that, if you will, plus-minus. And so I think that speaks to the job that, as I have highlighted, 95% of these patients content into Rhythm InTune. And so we as a company and that team has the opportunity to engage individually and there’s a high level of touch there and that’s incredibly valuable as people both getting expectations set in a way.
